Xue, J., Zhang, Kp., Zhu, Lj. et al. Inhibitory effects of Qushuanling Capsule (祛栓灵胶囊) on thrombus formation and platelet aggregation in rats., Chin. J. Integr. Med. 19, 137–142 (2013). https://doi.org/10.1007/s11655-012-1209-5
Jie Xue, Ke-ping Zhang, Lu-jia Zhu, et al. Inhibitory effects of Qushuanling Capsule (祛栓灵胶囊) on thrombus formation and platelet aggregation in rats[J]. Chinese Journal of Integrative Medicine, 2013,19(2):137-142.
Xue, J., Zhang, Kp., Zhu, Lj. et al. Inhibitory effects of Qushuanling Capsule (祛栓灵胶囊) on thrombus formation and platelet aggregation in rats., Chin. J. Integr. Med. 19, 137–142 (2013). https://doi.org/10.1007/s11655-012-1209-5DOI:
Jie Xue, Ke-ping Zhang, Lu-jia Zhu, et al. Inhibitory effects of Qushuanling Capsule (祛栓灵胶囊) on thrombus formation and platelet aggregation in rats[J]. Chinese Journal of Integrative Medicine, 2013,19(2):137-142. DOI: 10.1007/s11655-012-1209-5.
Inhibitory effects of Qushuanling Capsule (祛栓灵胶囊) on thrombus formation and platelet aggregation in rats
摘要
To investigate the effects of Qushuanling Capsule (祛栓灵胶囊 QSLC) on thrombus formation and platelet aggregation in rats. Arteriovenous bypass
venous thrombosis
and middle cerebral artery thrombosis models were used in rats to investigate the anti-thrombotic effects of QSLC
a compound of nine Chinese herbs. The platelet aggregation induced by adenosine diphosphate (ADP)
thrombin or arachidonic acid (AA)
as well as the contents of thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α (6-keto-PGF1α) in rat plasma and aortic walls
were determined to investigate the possible mechanisms of the anti-thrombotic effects of QSLC. After oral administration with QSLC for 7 days
arteriovenous bypass thrombosis was obviously suppressed compared with the model group
venous thrombosis was also obviously suppressed
rat behaviors were obviously improved
and brain infarct size as well as water content were also reduced. The platelet aggregation induced by ADP or thrombin was inhibited by QSLC
but the drug had no effect on AA-induced platelet aggregation and content of TXB2 and 6-keto-PGF1α in plasma and the aortic wall. These results suggest that QSLC can be used in the prevention and treatment of thrombotic diseases
and that its mechanism of action may be related to inhibition of platelet aggregation.
Abstract
To investigate the effects of Qushuanling Capsule (祛栓灵胶囊 QSLC) on thrombus formation and platelet aggregation in rats. Arteriovenous bypass
venous thrombosis
and middle cerebral artery thrombosis models were used in rats to investigate the anti-thrombotic effects of QSLC
a compound of nine Chinese herbs. The platelet aggregation induced by adenosine diphosphate (ADP)
thrombin or arachidonic acid (AA)
as well as the contents of thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α (6-keto-PGF1α) in rat plasma and aortic walls
were determined to investigate the possible mechanisms of the anti-thrombotic effects of QSLC. After oral administration with QSLC for 7 days
arteriovenous bypass thrombosis was obviously suppressed compared with the model group
venous thrombosis was also obviously suppressed
rat behaviors were obviously improved
and brain infarct size as well as water content were also reduced. The platelet aggregation induced by ADP or thrombin was inhibited by QSLC
but the drug had no effect on AA-induced platelet aggregation and content of TXB2 and 6-keto-PGF1α in plasma and the aortic wall. These results suggest that QSLC can be used in the prevention and treatment of thrombotic diseases
and that its mechanism of action may be related to inhibition of platelet aggregation.
Geerts WH, Berquist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133(6 Suppl):381S–453S.
Green D. Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism. Hematology 2009;1:259–266.
Adams JD, Wang R, Yang J, Lien EJ. Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chin Med 2006;1:3–17.
Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994;113:1209–1214.
Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986;17:472–476.
Gu ZL, Xie ML, Qian ZN. Ef fect of quercet in on chemiluminescence of human platelets induced by arachidonic acid. Acta Pharmacol Sin 1993;14:263–265.
Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983–989.
Fuster V, Chesebro JH. Mechanisms of unstable angina. N Engl J Med 1986;315:1023–1025.
Willerson JT, Hillis LD, Winniford M, Buja LM. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol 1986;8:245–250.
Wang GY, Gao YM, Hao YJ, Feng LQ. Study on pharmacological effects of Ginkgo biloba extract. Hubei J Tradit Chin Med (Chin) 2009;31:944–946.
Effects of total flavone of Abelmoschl Manihot L. Medic on the function of platelets and its mechanism
Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis, inflammatory reaction, and tissue damage in a rabbit model of toxin-heat and blood stasis syndrome
Effect of Chinese herbal medicine for activating blood circulation and detoxifying on expression of inflammatory reaction and tissue damage related factors in experimental carotid artery thrombosis rats
Inhibitory effect of panicoin on platelet activation and its mechanism
Effect of dauricine on redistribution of Glycoprotein IV in platelet membrane of patients with mitral stenosis
相关作者
暂无数据
相关机构
Department of Pharmacology, Anhui Medical University
Department of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences
Center of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences
Xuzhou Geriatrics Institute
Dept. of Cardiology, Institute of Cardiovascular Diseases, Tongji Medical University